CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm
Explore this paper's citation graph
Summary
The clinical efficacy and unique toxicities of individually developed CAR‐T cell products for the treatment of lymphomas, and their evolution from the laboratory bench to commercialization are summarized.
- Type
- article
- Published
- 2019-03-28
- Cited by
- 11
- References
- 86
- Access
- Open access
- OpenAlex
- https://openalex.org/W2933117197
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:133540801
Keywords
Chemoimmunotherapy, Medicine, Chimeric antigen receptor, Lymphoma, Follicular lymphoma
References
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
- Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
- The pharmacology of second-generation chimeric antigen receptors
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
- Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
- Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
- Peripheral T-cell lymphoma.
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
- Treatment of patients with advanced cancer with the natural killer cell line NK-92.
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
- Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Cited by
- Review: Myeloid-derived suppressor cells (MDSCs) – Will it become a therapeutic target for NonHodgkin Lymphoma?
- The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy
- The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
- Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective
- The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
- CAR-T cells in Hodgkin and T-cell lymphomas
- A Review of Immunotherapy in the Treatment of Tumors
- CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions
- MYH11 variants in thoracic aortic aneurysm pathophysiology: From bench to bedside
- Lymphocyte dynamics after CAR‐T therapy for non‐Hodgkin lymphoma
Related papers
- Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma.
- PO-0732: First line low doses RT and chemoimmunotherapy in stage II/IV follicular lymphoma patients
- Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
- Autologous retransplantation for patients with recurrent multiple myeloma
- Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
- Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.
- Novel targets in aggressive lymphoma.
- MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma
- Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma